A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®

Not Applicable

Recruiting

• Conditions: Postmenopausal Women With Osteoporosis at High Risk of Fracture
• Interventions: Drug: QL1206; Drug: Prolia®

• Registration Number: NCT07062978
• Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Brief Summary

This study is a multicenter, randomized, double-blind comparative study to valuating the efficacy and safety of QL1206 and Prolia® in postmenopausal women with osteoporosis at high risk of fracture.

Detailed Description

Not available

Study Timeline

• Study Start: 2025-06-27
• Status Verified: 2025-07
• Study First Submitted: 2025-07-03
• Study First Submitted QC: 2025-07-03
• Last Update Submitted: 2025-07-03
• Study First Posted: 2025-07-14
• Last Update Posted: 2025-07-14
• Primary Completion: 2027-01
• Study Completion: 2027-01-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 278

Inclusion Criteria

• Subjects who agree to participate in the study and sign the informed consent form.
• Postmenopausal women who can walk freely, aged 50-85 years (including 50 and 85 years old).
• Subjects whose absolute value of bone mineral density (BMD) in the lumbar or total hip area meets T values ≤ -2.5 and > -4.0.
• Subjects who must have at least one of the following risk factors: History of previous fragility fractures (occurring after the age of 40); history of hip fractures in fathers or mothers; increased bone turnover rate during screening; low body weight (BMI ≤ 19 kg/m2); advanced age (aged ≥ 65 years); current smoke.
• The duration of spontaneous amenorrhea was >2 years or >2 years after bilateral oophorectomy. If the status of bilateral oophorectomy is unknown or if the ovaries are preserved after hysterectomy, follicle stimulating hormone (FSH) levels >40mIU/mL may be used to confirm the status of postoperative menopause.

Exclusion Criteria

• Bone/metabolic disease.
• Hyperparathyroidism or hypoparathyroidism.
• Thyroid condition: Hyperthyroidism or hypothyroidism.
• Rheumatoid arthritis.
• Malabsorption syndrome.
• Renal disease - severe impairment of kidney function.
• Vitamin D defViciency (25-hydroxyvitamin D, 25OHD <20 ng/mL).
• Oral or dental diseases: previous or current evidence of mandibular osteomyelitis or osteonecrosis; Acute dental or mandibular disease requiring oral surgery; Planning invasive dental surgery; Failure to recover from dental or oral surgery.
• Previously used denosumab drugs.
• Use of intravenous bisphosphonates, fluoride, or strontium to treat osteoporosis within the last 5 years.
• OOral bisphosphonates (used for at least 3 years, or used for less than 3 years but more than 3 months, with the last use occurring <1 year before the ICF).
• Use of any of the following drugs within 6 weeks prior to screening that may affect bone metabolism.
• History of more than two vertebral fractures.
• Malignant tumors.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
QL1206	QL1206	QL1206 Denosumab injection(60 mg)
Prolia®	Prolia®	Prolia® Denosumab injection(60 mg)

Primary Outcome Measures

Name	Time	Method
Percent Change From Baseline in lumbar spine(LS)-BMD at Month 12	Baseline and 12 months	Percent Change From Baseline in lumbar spine(LS)-BMD at Month 12

Trial Locations

Locations (1)

Zhejiang Provincial People's Hospital Bijie Hospital; 🇨🇳 Guizhou, China

Zhejiang Provincial People's Hospital Bijie Hospital

🇨🇳Guizhou, China

Jun Zhang

Contact